A treatment which corrects errors in a person's genetic code has been approved for commercial use in Europe for the first time.
The European Commission has given Glybera marketing authorisation, meaning it can be sold throughout the EU.
It is a gene therapy for a rare disease which leaves people unable to properly digest fats.
Read it all.
To comment on this article: To article and comments
© 2013 Kendall S. Harmon. All rights reserved.
For original material from Titusonenine (such as articles and commentary by Dr. Harmon) permission to copy and distribute free of charge is granted, provided this notice, the logo, and the web site address are visible on all copies. For permission for use in for-profit publications, please email KSHarmon[at]mindspring[dot]com